CoChat
Sign Up
Cited by 151

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

The Role of Inflammation in Colon Cancer

Janakiram, Naveena B., Rao, Chinthalapally V.·2014·Advances in Experimental Medicine and Biology
DOI 10.1007/978-3-0348-0837-8_2
Open this paper in CoChat — free account

Abstract

Colorectal cancer (CRC) is the one of the leading causes of cancer-related deaths in the world. CRC is responsible for more than 600,000 deaths annually and incidence rates are increasing in most of the developing countries. Epidemiological and laboratory investigations suggest that environmental factors such as western style dietary habits, tobacco-smoking, and lack of physical activities are considered as risks for CRC. Molecular pathobiology of CRC implicates pro-inflammatory conditions to promote the tumor malignant progression, invasion, and metastasis. It is well known that patients with inflammatory bowel disease are at higher risk of CRC. Many evidences exist reiterating the link between Inflammation and CRC. Inflammation involves interaction between various immune cells, inflammatory cells, chemokines, cytokines, and pro-inflammatory mediators, such as cyclooxygenase (COX) and lipoxygenase (LOX) pathways, which may lead to signaling towards, tumor cell proliferation, growth, and invasion. Thus, this review will focus on mechanisms by which pro-inflammatory mediators and reactive oxygen/nitrogen species play a role in promoting CRC. Based on these mechanisms, various preventive strategies, involving anti-inflammatory agents, such as COX inhibitors, COX-LOX inhibitors, iNOS inhibitors, natural supplements/agents, and synthetic agents, that blocks the inflammatory pathways and suppress CRC are discussed in this review.

Overview

Integrity signals

Registry

Crossref · 10.1007/978-3-0348-0837-8_2

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 4 references

Research works printed but not linked: 192

  1. Abe Y, Hashimoto S, Horie T (1999) Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res 39(1):41–47 · DOI
  2. Ahn B, Ohshima H (2001) Suppression of intestinal polyposis in Apc (Min/+) mice by inhibiting nitric oxide production. Cancer Res 61:8357–8360
  3. Ahnen D, Hixson L, Albcrts D, Bogert C, Einspahr K, Brendel P, Gross N, Paranlea R, Pamukeu R (1994) Sulindac and its sulfone metabolite (FGN-1) both inhibit rat colon carcinogenesis but neither inhibit colonic proliferation. Proc Am Assoc Cancer Res 35:631
  4. Alberts DS et al (2005) What happened to the COXibs on the way to the cardiologist? Cancer Epidemiol. Biomarkers Prev 14:555–556 · DOI
  5. Alfaras I, Juan ME, Planas JM (2010a) Trans-resveratrol reduces precancerous colonic lesions in dimethylhydrazine-treated rats. J Agric Food Chem 58(13):8104–8110 · DOI
  6. Alfaras I, Pérez M, Juan ME, Merino G, Prieto JG, Planas JM, Alvarez AI (2010b) Involvement of breast cancer resistance protein (BCRP1/ABCG2) in the bioavailability and tissue distribution of trans-resveratrol in knockout mice. J Agric Food Chem 58(7):4523–4528 · DOI
  7. Al-Salihi MA, Pearman AT, Doan T, Reichert EC, Rosenberg DW, Prescott SM, Stafforini DM, Topham MK (2009) Transgenic expression of cyclooxygenase-2 in mouse intestine epithelium is insufficient to initiate tumorigenesis but promotes tumor progression. Cancer Lett 273(2):225–232 · DOI
  8. Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B, PreSAP Trial Investigators (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355(9):885–895 · DOI
  9. Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, Petasis NA, Blumberg RS, Serhan CN (2005) Proc Natl Acad Sci 102:7671–7676 · DOI
  10. Askling J, Dickman PW, Karlen P et al (2001) Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 120:1356–1362 · DOI
  11. Atreya I, Atreya R, Neurath MF (2008) NF-kappaB in inflammatory bowel disease. J Intern Med 263:591–596 · DOI
  12. Atreya I, Neurath MF (2008) Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies. Expert Rev Anticancer Ther 8:561–572 · DOI
  13. Avis I, Hong SH, Martinez A, Moody T, Choi YH, Trepel J et al (2001) Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. J Fed Am Soc Exp Biol 15:2007–2009
  14. Babbs CF (1990) Free radicals and etiology of colon cancer. Free Rad Biol Med 8:191–200 · DOI
  15. Bajad S, Coumar M, Khajuria R, Suri OP, Bedi KL (2003) Characterization of a new rat urinary metabolite of piperine by LC/NMR/MS studies. Eur J Pharm Sci 19(5):413–421 · DOI
  16. Bansal P, Sonnenberg A (1996) Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol 91(1):44–48
  17. Baron JA et al (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891–899 · DOI
  18. Bartosz G (1996) Peroxynitrite mediator of the toxic action of nitric oxide. Acta Biochim Polon 43:645–660 · DOI
  19. Belliveau P, Graham AM (1984) Mesenteric desmoid tumor in Gardener’s syndrome treated by sulindac. Dis Colon Rectum 27:53–54 · DOI
  20. Bhat BG, Chandrasekhara N (1986) Studies on the metabolism of piperine: absorption, tissue distribution and excretion of urinary conjugates in rats. Toxicology 40(1):83–92 · DOI
  21. Bias P, Buchner A, Klesser B, Laufer S (2004) The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial. Am J Gastroenterol 99:611–618 · DOI
  22. Bombardier C et al VIGOR Study Group (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343:1520–1528 · DOI
  23. Boolbol SK, Dannenberg AJ, Chadburn A et al (1996) Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56:2556–2560
  24. Bortuzzo C, Hanif R, Kashfi K, Staiano-Coico L, Shiff SJ, Rigas B et al (1996) The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells. Biochimica et Biophysical Acta 1300:240–246 · DOI
  25. Boudreau MD, Sohn KH, Rhee SH, Lee SW, Hunt JD, Hwang DH (2001) Suppression of tumor cell growth both in nude mice and in culture by n-3 polyunsaturated fatty acids: mediation through cyclooxygenase-independent pathways. Cancer Res 61(4):1386–1391
  26. Brown JR, DuBois RN (2005) COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 23:2840–2855 · DOI · Paper page
  27. Byrum RS, Goulet JL, Griffiths RJ, Koller BH (1997) Role of the 5-lipoxygenase-activating protein (FLAP) in murine acute inflammatory responses. J Exp Med 185:1065–1075 · DOI
  28. Calviello G, Di Nicuolo F, Gragnoli S, Piccioni E, Serini S, Maggiano N, Tringali G, Navarra P, Ranelletti FO, Palozza P (2004) n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1alpha induction pathway. Carcinogenesis 25(12):2303–2310 · DOI
  29. Campbell EL, MacManus CF, Kominsky DJ, Keely S, Glover LE, Bowers BE, Scully M, Bruyninckx WJ, Colgan SP (2010) Resolvin E1-induced intestinal alkaline phosphatase promotes resolution of inflammation through LPS detoxification. Proc Natl Acad Sci U S A 107(32):14298–14303 · DOI
  30. Cannizzo F Jr, Broitman SA (1989) Post promotional effects of dietary marine or safflower oils on large bowel or pulmonary implants of CT-26 in mice. Cancer Res 49(15):4289–4294
  31. Castellone MD, Teramoto H, Gutkind JS (2006) Cyclooxygenase-2 and colorectal cancer chemoprevention: the beta-catenin connection. Cancer Res 66:11085–11088 · DOI
  32. Cerutti P (1985) Prooxidant states and tumor promotion. Science 227:375–381 · DOI
  33. Chan AT, Giovannucci EL, Meyerhardt JA et al (2005) Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 294(8):914–923 · DOI
  34. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21(4B):2895–2900
  35. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Smithies O, Langenbach R (2000a) Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60(17):4705–4708
  36. Chulada PC, Thompson MB, Mahler JF et al (2000b) Genetic disruption of Ptgs-1 as well as Ptgs-2 reduces intestinal tumorigenesis in Min mice. Cancer Res 60:4706–4708
  37. Cicero AF, Derosa G, Gaddi A (2005) Combined lipoxygenase/cyclo-oxygenase inhibition in the elderly: the example of licofelone. Drugs Aging 22:393–403 · DOI
  38. Claria J, Serhan CN (1995) Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell—leukocyte interactions. Proc Natl Acad Sci 92:9475–9479 · DOI
  39. Clevers H (2004) At the crossroads of inflammation and cancer. Cell 118:671–674 · DOI
  40. Cockbain AJ, Toogood GJ, Hull MA (2012) Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer. Gut 61:135–149 · DOI
  41. Colon AL, Menchen L, Lizasoain I et al (2000) Inducible nitric oxide synthase activity is expressed not only in inflamed but also in normal colonic mucosa in patients with ulcerative colitis: a potential prognostic marker. Am J Gastroenterol 95:1371–1373 · DOI
  42. Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, Beaudeux JL (2010) Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 54(1):7–16 · DOI
  43. Crowell JA, Steele VE, Sigman CC, Fay JR (2003) Is inducible nitric oxide synthase a target for chemoprevention? Mol Cancer Ther 2:815–823
  44. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, Dubois RN (2005) Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 23:254–266 · DOI
  45. Darshan S, Doreswamy R (2004) Patented antiinflammatory plant drug development from traditional medicine. Phytother Res 18(5):343–357 · DOI · Paper page
  46. Ding XZ, Iversen P, Cluck MW et al (1999) Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochem Biophys Res Commun 261:218–223 · DOI
  47. Ding XZ, Tong WG, Adrian TE (2003) Multiple signal pathways are involved in the mitogenic effect of 5(S)- HETE in human pancreatic cancer. Oncology 65:285–294 · DOI
  48. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137–148 · DOI
  49. Erdman SE, Sohn JJ, Rao VP et al (2005) CD4CD25 regulatory lymphocytes induce regression of intestinal tumors in ApcMin/ mice. Cancer Res 65:3998–4004 · DOI · Paper page
  50. Feagins LA, Souza RF, Spechler SJ (2009) Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol 6:297–305 · DOI
  51. Fiorucci S, Meli R, Bucci M, Cirino G (2001) Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? Biochem Pharmacol 62:1433–1438 · DOI
  52. Freedman AN et al (1998) Aspirin use and p53 expression in colorectal cancer. Cancer Detect Prev 22:213–218 · DOI
  53. Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, Gescher AJ (2005) Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 14(1):120–125 · DOI
  54. Gewirtz AT, Collier-Hyams LS, Young AN, Kucharzik T, Guilford WJ, Parkinson JF et al (2002) Lipoxin A4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J Immunol 168(10):5260–5267 · DOI
  55. Giardello FM, Hamilton SR, Krush AJ, Piantodosi S, Hylind LM, Cleano P, Booker SV, Robinson RC, Offerhaus GJA (1993) Treatment of colonic rectal adenomas with sulindac in familial adenomatous polyposis. N Eng J Med 328:1313–1316 · DOI
  56. Giovannucci E (1999) The prevention of colorectal cancer by aspirin use. Biomed Pharmacother 53:303–308 · DOI
  57. Giovannucci E et al (1994) Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 121:241–246 · DOI
  58. Goel A, Kunnumakkara AB, Aggarwal BB (2008) Curcumin as “Curecumin”: from kitchen to clinic. Biochem Pharmacol 75(4):787–809 · DOI
  59. Goldstein BD, Witz G (1990) Free radicals and carcinogenesis. Free Radic Res Commun 11:3–10 · DOI
  60. Goulet JL, Snouwaert JN, Latour AM, Coffman TM, Koller BH (1994) Altered inflammatory responses in leukotriene-deficient mice. Proc Natl Acad Sci USA 91(26):12852–12856 · DOI
  61. Greenberg ER, Baron JA, Freeman DH, Mandel JS, Haile R (1993) Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst 85:912–916 · DOI
  62. Griffiths RJ, Smith MA, Roach ML, Stock JL, Stam EJ, Milici AJ et al (1997) Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice. J Exp Med 185:1123–1129 · DOI
  63. Gupta RA, Dubois RN (2001) Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nature Rev Cancer 1:11–21 · DOI
  64. Haklar G, Sayin-Özveri E, Yüksel M, Aktan AÖ, Yalçin AS (2001) Different kinds of reactive oxygen and nitrogen species were detected in colon and breast tumors. Cancer Lett 165(2):219–224 · DOI
  65. Hammad H, de Heer HJ, Soullie T, Hoogsteden HC, Trottein F, Lambrecht BN (2003) Prostaglandin D2 inhibits airway dendritic cell migration and function in steady state conditions by selective activation of the D prostanoid receptor 1. J Immunol 171:3936–3940 · DOI
  66. Hao XP, Pretlow TG, Rao JS, Pretlow TP (2001) Inducible nitric oxide synthase (iNOS) is expressed similarly in multiple aberrant crypt foci and colorectal tumors from the same patients. Cancer Res 61:419–422
  67. Harris RE, Beebe-Donk J, Doss H, Burr D (2005) Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade. Oncol Rep 13:559–583
  68. Hawk ET, Levin B (2005) Colorectal cancer prevention. J Clin Oncol 23:378 · DOI
  69. Hofseth LJ, Hussain SP, Wogan GN, Harris CC (2003) Nitric oxide in cancer and chemoprevention. Free Radic Biol Med 34:955–968 · DOI
  70. Hong SH, Avis I, Vos MD, Martinez A, Treston AM, Mulshine JL (1999) Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res 59:2223–2228
  71. Ishida T, Yoshida M, Arita M, Nishitani Y, Nishiumi S, Masuda A et al (2009) Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. Inflammation and Bowel Diseases 16(1):87–95 · DOI
  72. Ishida T, Yoshida M, Arita M, Nishitani Y, Nishiumi S, Masuda A, Mizuno S, Takagawa T, Morita Y, Kutsumi H, Inokuchi H, Serhan CN, Blumberg RS, Azuma T (2010) Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. Inflamm Bowel Dis 16(1):87–95 · DOI
  73. Jacoby RF, Marshall DJ, Newton MA, Novakovic K, Tutsch K, Cole CE et al (1996) Chemoprevention of spontaneous intestinal adenomas in APC Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 56:710–714
  74. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA (2000) The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res 60:5040–5044
  75. Janakiram NB, Rao CV (2012) iNOS-selective inhibitors for cancer prevention: promise and progress. Future Med. Chem. 4(17):2193–2204 · DOI
  76. Janakiram NB, Indranie C, Malisetty SV, Jagan P, Steele VE, Rao CV (2008) Chemoprevention of colon carcinogenesis by oleanolic acid and its analog in male F344 rats and modulation of COX-2 and apoptosis in human colon HT-29 cancer cells. Pharm Res 25(9):2151–2157 · DOI
  77. Janakiram NB, Mohammed A, Rao CV (2011) Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer. Cancer Metastasis Rev 30(3–4):507–523 · DOI
  78. Janakiram NB, Mohammed A, Ravillah D, Choi C-I, Zhang Y, Desai D, Amin S and Rao CV. (2013) Chemopreventive effects of PBI-Se, a selenium-containing analog of PBIT, on AOM-induced aberrant crypt foci in F344 rats. Oncol Rep 30(2):952--960 · DOI
  79. Juan ME, Alfaras I, Planas JM (2010) Determination of dihydroresveratrol in rat plasma by HPLC. J Agric Food Chem 58(12):7472–7475 · DOI
  80. Juan ME, Alfaras I, Planas JM (2012) Colorectal cancer chemoprevention by trans-resveratrol. Pharmacol Res 65(6):584–591 · DOI
  81. Juarez-Oropeza MA, Diaz-Zagoya JC, Rabinowitz JL (1987) In vivo and in vitro studies of hypocholesterolemic effects of diosgenin in rats. Int J Biochem 19(8):679–683 · DOI
  82. Kato T, Hancock RL, Mohammadpour H, McGregor B, Manalo P, Khaiboullina S, Hall MR, Pardini L, Pardini RS (2002) Influence of omega-3 fatty acids on the growth of human colon carcinoma in nude mice. Cancer Lett 187(1–2):169–177 · DOI
  83. Kawamori T, Lubet R, Steele VE, Kelloff GJ, Kaskey RB, Rao CV, Reddy BS (1999) Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 59(3):597–601
  84. Kawamori T, Rao CV, Seibert K, Reddy BS (1998) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58:409–412
  85. Kawamori T, Takahashi M, Watanabe K et al (2000) Suppression of azoxymethane-induced colonic aberrant crypt foci by a nitric oxide synthase inhibitor. Cancer Lett 148:33–37 · DOI
  86. Kawamori T, Tanaka T, Hara A, Yamahara J, Mori H (1995) Modifying effects of naturally occurring products on the development of colonic aberrant crypt foci induced by azoxymethane in F344 rats. Cancer Res 55(6):1277–1282
  87. Kudo T, Narisawa T, Abo S (1980) Antitumor activity of indomethacin on methylazoxymethanol-induced large bowel tumors in rats. Gann 71(2):260–264
  88. Kune GA, Kune S, Watson LF (1988) Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988 48:4399–4404. Reprinted Int J Epidemiol 2007 36:951–956 · DOI
  89. Kwon CS, Sohn HY, Kim SH, Kim JH, Son KH, Lee JS, Lim JK, Kim JS (2003) Anti-obesity effect of Dioscorea nipponica Makino with lipase-inhibitory activity in rodents. Biosci Biotechnol Biochem 67(7):1451–1456 · DOI
  90. La Vecchia C et al (1977) Aspirin and colorectal cancer. Br J Cancer 76:675–677 · DOI
  91. Lagares-Garcia JA, Moore RA, Collier B, Heggere M, Diaz F, Qian F (2001) Nitric oxide synthase as a marker in colorectal carcinoma. Am J Surg 67:709–713 · DOI · Paper page
  92. Laine L, Wogen J, Yu H (2003) Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs. Gastroenterology 125:389–395 · DOI
  93. Lakatos PL, Lakatos L (2008) Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol 14:3937–3947 · DOI
  94. Laybayle D, Fischer D, Vielh P, Frouhin F, Pariente A, Bories C, Duhamael O, Trousset M, Atti P (1991) Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101:635–639 · DOI
  95. Liu J (1995) Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol 49:57–68 · DOI
  96. Logan RF, Little J, Hawtin PG, Hardcastle JD (1993) Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case—control study of subjects participating in the Nottingham faecal occult blood screening programme. Br Med J 307:285–289 · DOI
  97. Mahato SB, Sen S (1997) Advances in triterpenoid research, 1990–1994. Phytochemistry 44(7):1185–1236 · DOI
  98. Mahmoud NN, Dannenberg AJ, Mestre J et al (1998) Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Medline Surg 124:225–231 · DOI
  99. Marnett LJ (1992) Aspirin and potential role of prostaglandins in colon cancer. Cancer Res 52:5575–5589
  100. Martel-Pelletier J, Lajeunesse D, Reboul P, Pelletier JP (2003) Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 62:501–509 · DOI
  101. Martinez ME, McPherson RS, Levin B, Annegers JF (1995) Aspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals. Cancer Epidemiol Biomarkers Prev 4:703–707
  102. McAnuff MA, Harding WW, Omoruyi FO, Jacobs H, Morrison EY, Asemota HN (2005) Hypoglycemic effects of steroidal sapogenins isolated from Jamaican bitter yam, Dioscorea polygonoides. Food Chem Toxicol 43(11):1667–1672 · DOI
  103. Meira LB, Bugni JM, Green SL et al (2008) DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest 118:2516–2525
  104. Metzger U, Meier J, Uhlschmid G, Weihe H (1984) Influence of various prostglandin synthesis inhibitors on DMH-induced rat colon cancer. Dis Colon Rectum 27:366–369 · DOI
  105. Mohammed A, Janakiram NB, Li Q, Choi CI, Zhang Y, Steele VE, Rao CV (2011) Chemoprevention of colon and small intestinal tumorigenesis in APCMin/+ Mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention. Cancer Prev Res 4(12):2015–2026 · DOI
  106. Moorghen M, Ince P, Finney KJ, Sunter JP, Appleton DR, Watson AJA (1988) A protective effect of sulindac against chemically—induced primary colonic tumors in mice. J Pathol 156:341–347 · DOI
  107. Moorghen M, Orde M, Finney KJ, Appleton DR, Watson AJ (1998) Sulindac enhances cell proliferation in DMH-treated mouse colonic mucosa. Cell Prolif 31:59–70 · DOI
  108. Moreau M, Daminet S, Martel-Pelletier J, Fernandes J, Pelletier JP (2005) Superiority of the gastroduodenal safety profile of licofelone over rofecoxib, a COX-2 selective inhibitor, in dogs. J Vet Pharmacol Ther 28:81–86 · DOI
  109. Mund RC, Pizato N, Bonatto S, Nunes EA, Vicenzi T, Tanhoffer R, de Oliveira HH, Curi R, Calder PC, Fernandes LC (2007) Decreased tumor growth in Walker 256 tumor-bearing rats chronically supplemented with fish oil involves COX-2 and PGE2 reduction associated with apoptosis and increased peroxidation. Prostaglandins Leukot Essent Fatty Acids 76(2):113–120 · DOI
  110. Murata T, Lin MI, Aritake K et al (2008) Role of prostaglandin D2 receptor DP as a suppressor of tumor hyper-permeability and angiogenesis in vivo. Proc Natl Acad Sci 105(50):20009–20014 · DOI
  111. Muscat JE, Stellman SD, Wynder EL (1994) Non-steroidal anti-inflammatory drugs and colorectal cancer. Cancer 74:1847–1854 · DOI
  112. Nalini N, Manju V, Menon VP (2006) Effect of spices on lipid metabolism in 1, 2-dimethylhydrazine-induced rat colon carcinogenesis. J Med Food 9(2):237–245 · DOI
  113. Nam KT, Oh SY, Ahn B, Kim YB, Jang DD, Yang KH et al (2004) Decreased Helicobacter pylori associated gastric carcinogenesis in mice lacking inducible nitric oxide synthase. Gut 20(53):1250–1255 · DOI
  114. Narisawa T, Satoh M, Sano M, Takahashi T (1993) Inhibition of initiation and promotionon N-methylnitrosourea-inducedcolon carcinogenesisin rats by nonsteroidal anti-inflammatory agent indomethacin. Carcinogenesis (London) 14:1493–1497 · DOI
  115. Narisawa T et al (1981) Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment. Cancer Res 41:1954–1957
  116. Nguyen AV, Martinez M, Stamos MJ, Moyer MP, Planutis K, Hope C, Holcombe RF (2009) Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Manag Res 1:25–37 · DOI
  117. Nieto N, Torres MI, Ríos A, Gil A (2002) Dietary polyunsaturated fatty acids improve histological and biochemical alterations in rats with experimental ulcerative colitis. J Nutr 132:11–19 · DOI
  118. Nussmeier NA et al (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352:1081–1091 · DOI
  119. Oh SF, Vickery TW, Serhan CN (2011) Chiral lipidomics of E-series resolvins: aspirin and the biosynthesis of novel mediators. Biochim Biophys Acta 1811(11):737–747 · DOI
  120. Ohd JF, Nielsen CK, Campbell J, Landberg G, Lofberg H, Sjolander A (2003) Expression of the leukotriene D4 receptor CysLT1, COX-2, colorectal adenocarcinomas. Gastroenterology 124:57–70 · DOI
  121. Ohshima H, Bartsch H (1994) Chronic infection and inflammatory processes as cancer risk factors: possible role of NO in carcinogenesis. Mutat Res 305:253–264 · DOI
  122. Orner GA, Dashwood WM, Blum CA, Daz GD, Li Q, Dashwood RH (2003) Suppression of tumorigenesis in the Apc(Min) mouse: down-regulation of b-catenin signaling by a combination of tea plus sulindac. Carcinogenesis 24:263–267 · DOI
  123. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM (1996a) Suppression of intestinal polyposis in Apc delta 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87(5):803–809 · DOI
  124. Oshima M, Dinchuk JE, Kargman SL (1996b) Suppression of intestinal polyposis in APCΔ716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell 87:803–809 · DOI
  125. Oshima M, Murai N, Kargman S et al (2001) Chemoprevention of intestinal polyposis in the APCΔ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 61:1733–1740
  126. Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS, West KP, Booth TD, Perloff M, Crowell JA (2010) Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 70:7392–7399 · DOI
  127. Peleg II, Maibach HT, Brown SH, Wilcox CM (1994) Aspirin and non-steroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 154:394–399 · DOI
  128. Piyachaturawat P, Glinsukon T, Toskulkao C (1983) Acute and subacute toxicity of piperine in mice, rats and hamsters. Toxicol Lett 16(3–4):351–359 · DOI
  129. Pizato N, Bonatto S, Yamazaki RK, Aikawa J, Nogata C, Mund RC, Nunes EA, Piconcelli M, Naliwaiko K, Curi R, Calder PC, Fernandes LC (2005) Ratio of n6 to n-3 fatty acids in the diet affects tumor growth and cachexia in Walker 256 tumor-bearing rats. Nutr Cancer 53(2):194–201 · DOI
  130. Pollard M, Luckert PH (1980) Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors. Cancer Treat Rep 64:1323–1327
  131. Pollard M, Luckert PH (1984) Effect of piroxicam on primary intestinal tumors induced in rats by N-methylnitrosourea. Cancer Left 25:117–121 · DOI
  132. Pollard M, Luckert PH (1981) Treatment of chemically-induced intestinal cancers with indomethacin. Proc Soc Exp Biol Med 167:161–164 · DOI
  133. Qiao L, Kozoni V, Tsioulias GJ, Koutsos MI, Hanif R, Shiff SJ et al (1995) Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim et Biophys Acta 1258:215–223 · DOI
  134. Rachmilewitz D, Stamler JS, Bachwich D, Karmeli F, Ackerman Z, Podolsky DK (1995) Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn’s disease. Gut 36:718–723 · DOI
  135. Raju J, Mehta R (2009) Cancer chemopreventive and therapeutic effects of diosgenin, a food saponin. Nutr Cancer 61(1):27–35 · DOI
  136. Raju J, Patlolla JM, Swamy MV, Rao CV (2004) Diosgenin, a steroid saponin of Trigonella foenum graecum (Fenugreek), inhibits azoxymethane-induced aberrant crypt foci formation in F344 rats and induces apoptosis in HT-29 human colon cancer cells. Cancer Epidemiol Biomarkers Prev 13(8):1392–1398 · DOI
  137. Rao CV (2004) Nitric Oxide signaling in colon cancer chemoprevention. Mut Res 555:107–119 · DOI
  138. Rao CV, Cooma I, Rodriguez JG, Simi B, El-Bayoumy K, Reddy BS (2000) Chemoprevention of familial adenomatous polyposis development in the APC(min) mouse model by 1, 4-phenylene bis(methylene) selenocyanate. Carcinogenesis 21:617–621 · DOI
  139. Rao CV, Cooma I, Simi B, Manning PT, Connor JR, Reddy BS (2002) Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res 62:165–170
  140. Rao CV, Kawamori T, Hamid R, Reddy BS (1999) Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase—selective inhibitor. Carcinogenesis 20:641–644 · DOI
  141. Rao CV, Reddy BS, Steele VE, Wang CX, Liu X, Ouyang N, Patlolla JM, Simi B, Kopelovich L, Rigas B (2006) Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol Cancer Ther 6:1530–1538
  142. Rao CV, Reddy BS (2004) NSAIDs and chemoprevention. Curr Cancer Drug Targets 4:29–42 · DOI
  143. Rao CV, Rivenson A, Simi B, Zang E, Kelloff G, Steele V, Reddy BS (1995) Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 55:1464–1472
  144. Reddy BS, Maruyama H, Kelloff G (1987) Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal anti-inflammatory drug, during different stages of rat colon tumor development. Cancer Res 47:5340–5346
  145. Reddy BS, Rao CV, Rivenson A, Kelloff G (1993) Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis (London) 14:1493–1497 · DOI
  146. Reddy BS, Rao CV (2002) Novel approaches for colon cancer prevention by COX-2 inhibitors. J Environ Pathol Toxicol Oncol 21:155–164 · DOI
  147. Rigau J, Pique JM, Rubio E, Planas R, Tarrech JM, Bordas JM (1991) Effect of long-term sulindac therapy on colonic polyposis. Ann Intern Med 115:952–954 · DOI
  148. Sale S, Tunstall RG, Ruparelia KC, Potter GA, Steward WP, Gescher AJ (2005) Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3, 4, 5, 4′-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells. Int J Cancer 115(2):194–201 · DOI
  149. Sandler RS et al (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348:883–890 · DOI
  150. Schleiffer R, Duranton B, Gossé F, Bergmann C, Raul F (2000) Nitric oxide synthase inhibition promotes carcinogen-induced preneoplastic changes in the colon of rats. Nitric Oxide 4(6):583–589 · DOI
  151. Schneider Y, Duranton B, Gossé F, Schleiffer R, Seiler N, Raul F (2001) Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis. Nutr Cancer 39(1):102–107 · DOI
  152. Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5:138–146 · DOI
  153. Sengottuvelan M, Nalini N (2006) Dietary supplementation of resveratrol suppresses colonic tumour incidence in 1, 2-dimethylhydrazine-treated rats by modulating biotransforming enzymes and aberrant crypt foci development. Br J Nutr 96(1):145–153 · DOI
  154. Serhan CN (1997) Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL). Prostaglandins 53:107–137 · DOI
  155. Serhan CN (2002) Lipoxins and aspirin-triggered 15-epilipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. Prostaglandins Other Lipid Mediat 68–69:4333–4455
  156. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP (2004) Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10(20):6847–6854 · DOI
  157. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ, Steward WP (2001) Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 7:1894–1900
  158. Shpitz B, Giladi N, Sagiv E, Lev-Ari S, Liberman E, Kazanov D, Arber N (2006) Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. Digestion 74(3–4):140–144 · DOI
  159. Silverstein FE et al (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 284:1247–1255 · DOI
  160. Skinner SA, Penney AG, O’Brien PE (1991) Sulindac inhibits the rate of growth and appearance of colon tumor in the rat Arch Surg 126:1094–1096 · DOI
  161. Smalley WE, DuBois RN (1997) Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 39:1–20 · DOI
  162. Smith WL (1992) Prostanoid biosynthesis and mechanisms of action. Am J Physiol 263:F181–F191
  163. Solomon SD et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071–1080 · DOI
  164. Son IS, Kim JH, Sohn HY, Son KH, Kim JS, Kwon CS (2007) Antioxidative and hypolipidemic effects of diosgenin, a steroidal saponin of yam (Dioscorea spp.), on high-cholesterol fed rats. Biosci Biotechnol Biochem 71(12):3063–3071 · DOI
  165. Spagnesi MT, Tonelli F, Dolara P, Caderni G, Valanzano R, Anastasi A, Bianchini F (1994) Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 106:362–366 · DOI
  166. Suh N, Reddy BS, DeCastro A, Paul S, Lee HJ, Smolarek AK, So JY, Simi B, Wang CX, Janakiram NB, Steele V, Rao CV (2011) Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/b-catenin/cyclin D1 signaling pathway in rats. Cancer Prev Res 4:1895–1902 · DOI
  167. Suh O, Mettlin C, Petrelli NJ (1993) Aspirin use, cancer, and polyps of the large bowel. Cancer 72:1171–1177 · DOI
  168. Swamy MV, Patlolla JM, Steele VE, Kopelovich L, Reddy BS, Rao CV (2006) Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res 66:7370–7377 · DOI
  169. Szaleczky E, Pronai L, Nakazawa H, Tulassay Z (2000) Evidence of in vivo peroxynitrite formation in patients with colorectal carcinoma, higher plasma nitrate/nitrite levels, and lower protection against oxygen free radicals. J Clin Gastroenterol 30:47–51 · DOI
  170. Tamir S, Tannenbaus SR (1996) The role of nitric oxide in carcinogenic process. Biochim Biophys Acta 1288:F31–F36
  171. Tenesa A, Dunlop MG (2009) New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet 10:353–358 · DOI
  172. Tessitore L, Davit A, Sarotto I, Caderni G (2000) Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21 (CIP) expression. Carcinogenesis 21(8):1619–1622 · DOI
  173. Thun MH, Namboodiri MM, Heath CW (1991) Aspirin use and reduced risk of fatal colon cancer. N Eng J Med 325:1593–1596 · DOI
  174. Togni V, Ota CC, Folador A, Júnior OT, Aikawa J, Yamazaki RK, Freitas FA, Longo R, Martins EF, Calder PC, Curi R, Fernandes LC (2003) Cancer cachexia and tumor growth reduction in Walker 256 tumor-bearing rats supplemented with N-3 polyunsaturated fatty acids for one generation. Nutr Cancer 46(1):52–58 · DOI
  175. Tong WG, Ding XZ, Talamonti MS, Bell RH, Adrian TE (2005) LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. Biochem Biophys Res Commun 335:949–956 · DOI
  176. Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, Umland JP, Pandher K, Lapointe JM, Saha S, Roach ML, Carter D, Thomas NA, Durtschi BA, McNeish JD, Hambor JE, Jakobsson PJ, Carty TJ, Perez JR, Audoly LP (2003) Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci USA 100:9044–9049 · DOI
  177. Ukil A, Maity S, Karmakar S, Datta N, Vedasiromoni JR, Das PK (2003) Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol 139:209–218 · DOI
  178. Vanamala J, Glagolenko A, Yang P, Carroll RJ, Murphy ME, Newman RA, Ford JR, Braby LA, Chapkin RS, Turner ND, Lupton JR (2008) Dietary fish oil and pectin enhance colonocyte apoptosis in part through suppression of PPAR delta/PGE2 and elevation of PGE3. Carcinogenesis 29(4):790–796 · DOI
  179. Velayos FS, Loftus EV, Jess T, Harmsen WS, Bida J, Zinsmeister AR, Tremaine WJ, Sandborn WJ (2006) Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterol 130:1941–1949 · DOI
  180. Waddel RW, Ganser GF, Cerise EJ, Loughry RW (1989) Sulindac for polyposis of the colon. Am J Surg 157:175–179 · DOI
  181. Waldner MJ, Neurath MF (2008) Cytokines in colitis associated cancer: potential drug targets? Inflamm Allergy Drug Targets 7:187–194 · DOI
  182. Walle T (2011) Bioavailability of resveratrol. Ann NY Acad Sci 1215:9–15 · DOI · Paper page
  183. Wan G, Kato N, Watanabe H (2000) High fat diet elevates the activity of inducible nitric oxide synthase and 1, 2 dimethyl-hydrazine induced aberrant crypt foci in colon of rats. Oncolo Rep 7:391–395
  184. Wang D, Dubois RN (2006) Review prostaglandins and cancer. Gut 55(1):115–122 · DOI
  185. West NJ, Clark SK, Phillips RKS, Hutchinson JM, Leicester RJ, Belluzzi A, Hull MA (2010) Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut. doi:10.1136/gut.2009.200642 · DOI
  186. Westbrook AM, Wei B, Braun J, Schiestl RH (2009) Intestinal mucosal inflammation leads to systemic genotoxicity in mice. Cancer Res 69:4827–4834 · DOI
  187. Winde G, Gumbinger HG, Osswald H, Kemper F, Bunte H (1993) The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: clinical results of a dose finding study on rectal sulindac administration. Int J Colorect Dis 8:13–17 · DOI
  188. Xu G, Ren G, Xu X, Yuan H, Wang Z, Kang L, Yu W, Tian K (2010) Combination of curcumin and green tea catechins prevents dimethylhydrazine-induced colon carcinogenesis. Food Chem Toxicol 48(1):390–395. doi:10.1016/j.fct.2009.10.027. Epub 25 Oct 2009 · DOI
  189. Xu W, Liu L, Charles IG (2002) Microencapsulated iNOS-expressing cells cause tumor suppression in mice. FASEB J 16:213–215
  190. Yagihashi N, Kasajima H, Sugai S et al (2000) Increased in situ expression of nitric oxide synthase in human colorectal cancer. Virchows Arch 436:109–114 · DOI
  191. Yamada T, Hoshino M, Hayakawa T, Ohhara H, Yamada H, Nakazawa T, Inagaki T, Iida M, Ogasawara T, Uchida A, Hasegawa C, Murasaki G, Miyaji M, Hirata A, Takeuchi T (1997) Dietary diosgenin attenuates subacute intestinal inflammation associated with indomethacin in rats. Am J Physiol 273(2):G355–G364
  192. Ziegler CC, Rainwater L, Whelan J, McEntee MF (2004) Dietary resveratrol does not affect intestinal tumorigenesis in Apc(Min/+) mice. J Nutr 134(1):5–10 · DOI

Cited by

Sorted by citations

See all 151

Metadata

Authors
Janakiram, N. B., & Rao, C. V.
Venue
Advances in Experimental Medicine and Biology
Publisher
Springer Basel
Published
2014
Pages
25-52
ISSN
  • 0065-2598
  • 2214-8019
DOI
10.1007/978-3-0348-0837-8_2
Cited by
151
References
4
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Role of Inflammation in Colon Cancer. https://app.cochat.ai/papers/10.1007/978-3-0348-0837-8_2
The paper
Janakiram, N. B., & Rao, C. V. (2014). The Role of Inflammation in Colon Cancer. Advances in Experimental Medicine and Biology. https://doi.org/10.1007/978-3-0348-0837-8_2